Disability

AudioEye Achieves HIPAA Compliance and SOC 2 Type II Certification, Strengthening Data Protection and Security Measures for Its Customers

New compliance and certification measures unlock opportunities in healthcare and enterprise TUCSON, Ariz., Sept. 26, 2024 /PRNewswire/ -- AudioEye, Inc. (Nasdaq:…

1 year ago

Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Nes-Ziona, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…

1 year ago

Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

-- Poster to be presented at ACR Convergence annual meeting -- TAMPA, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Pacira…

1 year ago

Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts

$185+ million in incremental orders for ACAM2000® and VIGIV to be delivered in 2024 and 2025GAITHERSBURG, Md., Sept. 25, 2024…

1 year ago

Ottobock Continues Providing Technical Service for Invictus Games Vancouver Whistler 2025

The medical technology company supports competitors in the first ever Winter hybrid Invictus GamesBURLINGTON, ON / ACCESSWIRE / September 24,…

1 year ago

Ottobock Continues Technical Service for Invictus Games Vancouver Whistler 2025

The medical technology company supports competitors in the first-ever Winter hybrid Invictus GamesAUSTIN, TX / ACCESSWIRE / September 24, 2024…

1 year ago

Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Nes-Ziona, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…

1 year ago

Potential of George Medicines’ novel, low-dose, triple combination pill to transform management of hypertension highlighted at global congress

London, UK 24 September 2024 – George Medicines, a late-stage, biopharmaceutical company addressing significant unmet need in the treatment of…

1 year ago

Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress

Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for…

1 year ago